Why this topic matters
If you are researching clinics that advertise peptide-related consultations, you will eventually come across the term compounded medicine. It is one of the most misunderstood parts of the Australian medicines framework.
Compounding is not a synonym for "approved", "safer", "more personalised" or "automatically legal". It has a narrower meaning. In practical terms, it usually refers to a pharmacist or healthcare practitioner preparing a medicine for a particular patient when a commercially manufactured product is not suitable.
The TGA defines compounding this way in its safety guidance: a medicine is compounded where it is required for a particular patient to meet that person's clinical needs and a commercially manufactured medicine is not suitable: TGA - Compounding safety information.
How compounded medicines differ from TGA-registered medicines
The cleanest distinction is this:
TGA-registered prescription medicines
- are entered on the ARTG
- have an AUST R number
- are evaluated by the TGA for quality, safety and efficacy before registration
Source: TGA - Prescription medicines
Compounded medicines
- are generally prepared for an individual patient
- rely on specific exemptions that recognise their one-off nature
- are not evaluated by the TGA for safety, quality or efficacy before supply
Source: TGA - Compounding safety information
That does not mean every compounded medicine is unlawful or inappropriate. It means it sits in a different regulatory bucket.
When compounding may be used
The TGA gives a straightforward example: compounding can be relevant where a patient needs a different formulation and a commercially manufactured option is not suitable, such as when a child cannot swallow tablets and an approved liquid form is unavailable.
The broader point is that compounding is intended for individual clinical need, not as a shortcut around the normal approval pathway.
The TGA has also said compounding should be reserved for exceptional clinical circumstances where suitable approved alternatives are unavailable, have failed or are unsuitable: TGA - Compounding safety information.
That is a useful lens for consumers. If a clinic presents compounding as the default first option for everyone, it is reasonable to ask why.
Why some peptide products may be discussed in compounding contexts
In the peptide space, some products people ask about are not ARTG-registered medicines. The TGA's April 2026 safety alert says unapproved peptide products are goods not included on the ARTG and warns about the rise in import, compounding, supply and advertising of these products: TGA - Unapproved peptide products safety alert.
That helps explain why compounding is discussed at all. In some cases, patients are not comparing one approved brand with another. They are looking at a category where:
- some products may be approved prescription medicines
- some may be unapproved therapeutic goods
- some may only be discussed in practice through compounding and named-patient dispensing arrangements
The key consumer point is not to assume all peptide-related medicines sit under one rule. They do not.
What rules apply to compounding in Australia
The TGA explains that there are legislative exemptions recognising the one-off nature of extemporaneous compounding. Because only small quantities are made specifically for an individual patient, a TGA manufacturing licence is not always required. At the same time, compounding is regulated by the states and territories in line with the Pharmacy Board's guidelines and professional practice obligations: TGA - Compounding safety information.
A few practical points follow from that:
Find a Clinic
Compare clinic profiles by stated telehealth or in-person access, focus area, and state.
- compounded medicines are not pre-approved by the TGA
- pharmacists still have to follow professional and legal standards
- state and territory pharmacy rules still matter
- quality controls are different from the ARTG registration process
The TGA's GMP guidance also notes that compounded and dispensed medicines are not exempt from meeting applicable quality standards under the Therapeutic Goods Act 1989: TGA - Understanding GMP for compounded medicines.
What compounding does not allow
This is the part many consumers do not see.
The TGA states that, outside certain hospital circumstances, it is unlawful for pharmacists to supply medicines they have compounded before receiving a prescription for a named patient: TGA - Compounding safety information.
The same TGA guidance warns that the compounding exemptions do not apply where products are compounded for bulk supply in anticipation of patients' needs before a prescription is received, and says commercial-like scale compounding can create added risks because the products are not subject to the same rigorous testing for safety and quality.
That is an important distinction for clinic comparison. A compliant pathway should sound like:
- consultation first
- prescribing decision second
- dispensing for a named patient through an appropriate pharmacy process
It should not sound like open retail stock being sold to the public.
What safety standards still apply
Even though compounded medicines are not evaluated by the TGA in the same way as registered medicines, that does not mean there are no standards.
Relevant safeguards can include:
- Pharmacy Board of Australia compounding guidelines
- state and territory pharmacy premises requirements
- professional practice standards
- quality assurance processes
- additional controls for sterile and injectable preparations
The TGA specifically notes that adherence to Pharmacy Board guidelines is particularly important for injectable compounded medicines because of infection and side-effect risks: TGA - Compounding safety information.
What to ask a clinic or pharmacy
If a clinic mentions a compounded medicine, ask:
- Why is compounding being used in this case?
- Is there an ARTG-registered alternative?
- Will the medicine be dispensed only after a named-patient prescription?
- Which pharmacy prepares it?
- What follow-up monitoring applies?
- What extra costs are involved?
That last point matters. Compounded medicines can involve separate consultation, dispensing and handling costs, which is why they are worth comparing carefully.
You may also want to read questions to ask your practitioner before starting any prescribed program and our guide to what the TGA says about peptide legality in Australia.
Final takeaway
Compounded medicines in Australia are not the same thing as TGA-registered medicines. They may be lawfully prepared in appropriate named-patient circumstances, but they are not pre-assessed by the TGA for safety, quality or efficacy in the way ARTG-registered prescription medicines are. That is why process, pharmacy standards and practitioner transparency matter so much.
If you are comparing clinics that advertise peptide-related consultations, do not treat "compounded" as a shortcut label. Ask why it is being used, how it is supplied and what monitoring applies, then browse the directory with those questions in mind.